mRNA vaccine helps CAR-T therapy in solid tumors with an overall response rate of 43%

At the ongoing AACR annual meeting, BioNTech announced the results of the first human clinical trial of BNT211, a next-generation CAR-T therapy targeting solid tumors

BNT211 is a potential "first-in-class" therapeutic strategy that combines a CLDN6 antigen-targeting CAR-T therapy with a CLDN6 antigen-expressing CARVac

▲The mechanism of action of BNT211 (Image source: BioNTech official website)

Preliminary clinical trial results presented at the AACR annual meeting included 16 patients who received CLDN6-targeted CAR-T therapy at a dose of 1x10^7 and two patients who received CAR-T therapy at a dose of 1x10^8, some of whom also received CARVac treatment

After 12 weeks of treatment, 4 patients who had a partial response had a deepening response, and one patient had a complete response after 18 weeks of treatment

"The anticancer effect observed in patients treated with the lowest dose of CAR-T cell therapy shows the potential of our CAR design and CARVac strategy

References:

[1] BioNTech Presents Positive Preliminary Phase 1/2 Data for First-in-Class CAR-T Program BNT211 at AACR.